The Supreme Court of Canada heard oral arguments in AstraZeneca v Apotex and reserved its decision about patent utility and the ‘promise doctrine’, in a case centring on pharmaceutical company AstraZeneca’s heartburn relief drug Nexium (esomeprazole magnesium).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AstraZeneca v Apotex, Astrazeneca, Apotex, patent, utility, gastric acid, Nexium, Supreme Court of Canada, promise doctrine,